» Articles » PMID: 19139138

Reporting and Interpretation of SF-36 Outcomes in Randomised Trials: Systematic Review

Overview
Journal BMJ
Specialty General Medicine
Date 2009 Jan 14
PMID 19139138
Citations 94
Authors
Affiliations
Soon will be listed here.
Abstract

Objective: To determine how often health surveys and quality of life evaluations reach different conclusions from those of primary efficacy outcomes and whether discordant results make a difference in the interpretation of trial findings.

Design: Systematic review.

Data Sources: PubMed, contact with authors for missing information, and author survey for unpublished SF-36 data.

Study Selection: Randomised trials with SF-36 outcomes (the most extensively validated and used health survey instrument for appraising quality of life) that were published in 2005 in 22 journals with a high impact factor.

Data Extraction: Analyses on the two composite and eight subdomain SF-36 scores that corresponded to the time and mode of analysis of the primary efficacy outcome.

Results: Of 1057 screened trials, 52 were identified as randomised trials with SF-36 results (66 separate comparisons). Only eight trials reported all 10 SF-36 scores in the published articles. For 21 of the 66 comparisons, SF-36 results were discordant for statistical significance compared with the results for primary efficacy outcomes. Of 17 statistically significant SF-36 scores where primary outcomes were not also statistically significant in the same direction, the magnitude of effect was small in six, moderate in six, large in three, and not reported in two. Authors modified the interpretation of study findings based on SF-36 results in only two of the 21 discordant cases. Among 100 additional randomly selected trials not reporting any SF-36 information, at least five had collected SF-36 data but only one had analysed it.

Conclusions: SF-36 measurements sometimes produce different results from those of the primary efficacy outcomes but rarely modify the overall interpretation of randomised trials. Quality of life and health related survey information should be utilised more systematically in randomised trials.

Citing Articles

High Body Mass Index Disrupts the Homeostatic Relationship Between Pain Inhibitory Control and the Symptomatology in Patients with Knee Osteoarthritis-A Cross-Sectional Analysis from the DEFINE Study.

Lacerda G, Fregni F, Battistella L, Imamura M NeuroSci. 2025; 6(1).

PMID: 39982266 PMC: 11843865. DOI: 10.3390/neurosci6010014.


Development of updated population norms for the SF-36 for Hungary and comparison with 1997-1998 norms.

Bato A, Brodszky V, Rencz F Health Qual Life Outcomes. 2025; 23(1):14.

PMID: 39962594 PMC: 11831779. DOI: 10.1186/s12955-025-02343-5.


Case Report: Treatment of a complex hand disfigurement injury by fully shaped reconstruction of a severed finger combined with ectopic banking.

Jia Z, Shi L, Gao W, Li H, Zhang J, Shi W Front Surg. 2024; 11:1488338.

PMID: 39703819 PMC: 11656348. DOI: 10.3389/fsurg.2024.1488338.


Kinesiological Rehabilitation in a Young Adult with Biceps Femoralis Arteriovenous Malformation: A Case Study.

Di Martino G, Della Valle C, Centorbi M, Bovolenta P, Fiorilli G, Calcagno G J Funct Morphol Kinesiol. 2024; 9(4).

PMID: 39584878 PMC: 11586994. DOI: 10.3390/jfmk9040225.


Role function in postmenopausal women during aromatase inhibitor therapy for breast cancer.

Melnyk H, Dickson V, Bender C, Yu G, Djukic M, Merriman J J Cancer Surviv. 2024; .

PMID: 39425854 DOI: 10.1007/s11764-024-01697-x.


References
1.
Revicki D, Hays R, Cella D, Sloan J . Recommended methods for determining responsiveness and minimally important differences for patient-reported outcomes. J Clin Epidemiol. 2008; 61(2):102-9. DOI: 10.1016/j.jclinepi.2007.03.012. View

2.
Wyrwich K, Tierney W, Wolinsky F . Further evidence supporting an SEM-based criterion for identifying meaningful intra-individual changes in health-related quality of life. J Clin Epidemiol. 1999; 52(9):861-73. DOI: 10.1016/s0895-4356(99)00071-2. View

3.
Revicki D, Gnanasakthy A, Weinfurt K . Documenting the rationale and psychometric characteristics of patient reported outcomes for labeling and promotional claims: the PRO Evidence Dossier. Qual Life Res. 2007; 16(4):717-23. DOI: 10.1007/s11136-006-9153-5. View

4.
Ioannidis J, Trikalinos T . An exploratory test for an excess of significant findings. Clin Trials. 2007; 4(3):245-53. DOI: 10.1177/1740774507079441. View

5.
Michael M, Tannock I . Measuring health-related quality of life in clinical trials that evaluate the role of chemotherapy in cancer treatment. CMAJ. 1998; 158(13):1727-34. PMC: 1229445. View